MEGALOBOX 2: NOMAD to Premiere in April 2021 on TOKYO MX & BS11
1.2.2021 10:30:00 EET | Business Wire | Press release
TMS Entertainment today announced that MEGALOBOX 2: NOMAD , the highly anticipated sequel to the internationally acclaimed anime series MEGALOBOX , will premiere in April 2021 on Japanese television networks TOKYO MX and BS11.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210131005078/en/
teaser visual of Nomad (Graphic: Business Wire)
MEGALOBOX , a series based on Tomorrow’s Joe by Asao Takamori (Ikki Kajiwara) and Tetsuya Chiba, was originally released in 2018 to commemorate the 50th anniversary of the original manga title.
Teaser Trailer and Visuals Revealed
The teaser trailer and visuals have also been revealed ahead of the broadcast.
Watch the teaser now: https://youtu.be/bjl0qMgrugQ
The striking teaser visual, drawn by the director Yo Moriyama, shows Joe standing with his gear covering the body full of scars. Seven years after Joe’s reign as the first Megalonia champion, we now find him calling himself Nomad. The accompanying teaser trailer reveals a glimpse of what had happened to Joe after the fateful match with Yuri in MEGALOBOX.
ABOUT MEGALOBOX 2: NOMAD
In the end, “Gearless” Joe was the one that reigned as the champion of Megalonia, a first ever megalobox tournament. Fans everywhere were mesmerized by the meteoric rise of Joe who sprung out from the deepest underground ring to the top in mere three months and without the use of gear. Seven years later, “Gearless” Joe was once again fighting in underground matches. Adorned with scars and once again donning his gear, but now known only as Nomad…
WEB: https://megalobox.com/
Twitter: https://twitter.com/joe50_megalobox
STAFF
Original Concept: Tomorrow’s Joe
Original Comic Books Created by Asao Takamori, Tetsuya Chiba / Published by Kodansha.
Director / Concept Designer: Yo Moriyama
Scenario: Katsuhiko Manabe, Kensaku Kojima
Character Designer: Ayumi Kurashima
Sub Character Designer: Naomi Kaneda
Music: mabanua
Animation production: TMS Entertainment Co., Ltd.
Produced by MEGALOBOX2 Project
CAST
Joe / NOMAD: Yoshimasa Hosoya
GANSAKU NANBU: Shiro Saito
YURI: Hiroki Yasumoto
SACHIO: Michiyo Murase
© Asao Takamori, Tetsuya Chiba/Kodansha/MEGALOBOX2 project. All Rights Reserved.
About TMS Entertainment
By maintaining a balance of creativity and business production, TMS Entertainment provides a one-stop shop for services from IP creation to consumer satisfaction improvement, centered around its animation production, licensing, and content businesses. TMS Entertainment has continuously produced much-loved anime titles in Japan, including "Lupin the 3rd," "Dr. STONE," and “MEGALOBOX” while connecting its library of over 12,000 episodes across a total of 420 titles to its global business.
WEB: https://www.tms-e.co.jp/global/
Twitter:
https://twitter.com/tmsanime
Facebook:
https://www.facebook.com/AnimeTMS
Instagram:
https://www.instagram.com/tmsanime/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210131005078/en/
Contact information
TMS Entertainment Co., Ltd. Paris Office
International Sales & Licensing
Cinzia Mariani
E-mail: tmsparis@tms-e.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 18:08:00 EEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubrutinib) plus next-generation BCL2 inhibitor BEQALZI™ (sonrotoclax; ZS), which continue to demonstrate rapid, deep, durable responses across multiple B-cell malignancies. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “BTK inhibition has reshaped the treatment of B-cell cancers, and we believe degradation is the next leap forwa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom